Myriad Genetics (Myriad Genetics) LT-Debt-to-Total-Asset : 0.12 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Myriad Genetics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.12.

Myriad Genetics's long-term debt to total assets ratio increased from Dec. 2022 (0.11) to Dec. 2023 (0.12). It may suggest that Myriad Genetics is progressively becoming more dependent on debt to grow their business.

Myriad Genetics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Myriad Genetics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics LT-Debt-to-Total-Asset Chart

Myriad Genetics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.15

0.20

0.06

0.11

0.12

Myriad Genetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.11	0.13	0.16	0.16	0.12

Myriad Genetics LT-Debt-to-Total-Asset Calculation

Myriad Genetics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	135.9	/	1146.5
	=	0.12

Myriad Genetics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	135.9	/	1146.5
	=	0.12

Myriad Genetics (NAS:MYGN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Myriad Genetics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics (Myriad Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

TWST NEO VCYT GH OPK LAB FLGT CSTL CDNA SHC TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN

Traded in Other Exchanges

MYD:Germany

Address

320 Wakara Way, Salt Lake City, UT, USA, 84108

Website

https://www.myriad.com

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Executives

Richard Bryan Riggsbee	officer: Chief Financial Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Nicole Lambert	officer: Chief Operating Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Margaret Ancona	officer: SVP, Chief of Staff	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong	officer: Chief Legal Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman	officer: Chief People Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro	director
Dale Muzzey	officer: Chief Scientific Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Kevin Richard Haas	officer: Chief Technology Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk	officer: Chief Accounting Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Lee Nisley Newcomer	director	264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Rashmi Kumar	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jayne B. Hart	officer: Executive VP Human Resources	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jerry S Lanchbury	officer: Senior V.P. - Research	320 WAKARA WAY, SALT LAKE CITY UT 84108